Document Detail

Risk of arterial thrombosis not increased by sorafenib or sunitinib.
MedLine Citation:
PMID:  20733133     Owner:  NLM     Status:  MEDLINE    
David R Minor
Related Documents :
11722993 - Thromboembolic disease and antithrombotic therapy in newborns.
438753 - Heparin and warfarin: use of anticoagulants in the prevention and treatment of venous t...
9530033 - Value of ct angiography for postoperative assessment of patients with iliac artery aneu...
Publication Detail:
Type:  Comment; Letter     Date:  2010-08-23
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  28     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-19     Completed Date:  2010-11-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e619; author reply e620     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / adverse effects*
Arterial Occlusive Diseases / chemically induced*
Benzenesulfonates / adverse effects*
Evidence-Based Medicine
Indoles / adverse effects*
Protein Kinase Inhibitors / adverse effects*
Pyridines / adverse effects*
Pyrroles / adverse effects*
Reproducibility of Results
Risk Assessment
Risk Factors
Thromboembolism / chemically induced*
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Benzenesulfonates; 0/Indoles; 0/Protein Kinase Inhibitors; 0/Pyridines; 0/Pyrroles; 0/sorafenib; 0/sunitinib
Comment On:
J Clin Oncol. 2010 May 1;28(13):2280-5   [PMID:  20351323 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment o...
Next Document:  Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and mul...